About Ocera Therapeutics (NASDAQ:TZYM)
Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:TZYM
- CUSIP: N/A
- Web: www.ocerainc.com/
- Trailing P/E Ratio:
- Foreward P/E Ratio: -1.28
- P/E Growth:
- Return on Equity: -215.86%
- Return on Assets: -101.91%
Frequently Asked Questions for Ocera Therapeutics (NASDAQ:TZYM)
What is Ocera Therapeutics' stock symbol?
Ocera Therapeutics trades on the NASDAQ under the ticker symbol "TZYM."
Who are some of Ocera Therapeutics' key competitors?
Some companies that are related to Ocera Therapeutics include Biogen (BIIB), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Abcam Plc (ABC), Anika Therapeutics (ANIK), Myovant Sciences Ltd (MYOV), Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Mirna Therapeutics (SYBX), Syndax Pharmaceuticals (SNDX), Fortress Biotech (FBIO), Mereo BioPharma Group PLC (MPH), Strongbridge Biopharma PLC (SBBP), Kamada (KMDA), Kadmon Holdings (KDMN), Peregrine Pharmaceuticals (PPHM) and Vericel Corporation (VCEL).
Who are Ocera Therapeutics' key executives?
Ocera Therapeutics' management team includes the folowing people:
- Linda S. Grais M.D., President, Chief Executive Officer, Director
- Michael Byrnes, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
- Stan Bukofzer M.D., Chief Medical Officer
- Steven P. James, Lead Independent Director
- Willard H. Dere M.D., Director
- Nina S. Kjellson, Independent Director
- Anne M. VanLent, Independent Director
- Eckard Weber M.D., Independent Director
How do I buy Ocera Therapeutics stock?
Shares of Ocera Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ocera Therapeutics' stock price today?
MarketBeat Community Rating for Ocera Therapeutics (NASDAQ TZYM)MarketBeat's community ratings are surveys of what our community members think about Ocera Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Ocera Therapeutics stock can currently be purchased for approximately $0.48.
Consensus Ratings for Ocera Therapeutics (NASDAQ:TZYM) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Ocera Therapeutics (NASDAQ:TZYM)
Analysts' Ratings History for Ocera Therapeutics (NASDAQ:TZYM)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Ocera Therapeutics (NASDAQ:TZYM)Earnings History by Quarter for Ocera Therapeutics (NASDAQ TZYM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/28/2013||Q4 2012||($0.30)||($0.18)||$1.70 million||$1.60 million||View||N/A|
|11/8/2012||Q312||($0.29)||($0.16)||$1.99 million||$1.80 million||View||N/A|
Earnings Estimates for Ocera Therapeutics (NASDAQ:TZYM)
Current Year EPS Consensus Estimate: $-0.170 EPS
Next Year EPS Consensus Estimate: $-0.370 EPS
Dividend History for Ocera Therapeutics (NASDAQ:TZYM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Ocera Therapeutics (NASDAQ:TZYM)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Ocera Therapeutics (NASDAQ:TZYM)
Latest Headlines for Ocera Therapeutics (NASDAQ:TZYM)
Ocera Therapeutics (TZYM) Chart for Wednesday, October, 18, 2017